San Francisco, CA, United States of America

Arvin C Dar

This inventor holds 10 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Icahn School of Medicine at Mount Sinai, University of California. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Arvin C Dar. Retrieved from https://idiyas.com/inventor/arvin-c-dar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 86(Granted Patents)

Location History:

San Francisco, CA (US) (2014 - 2018)
New York, NY (US) (2019 - 2021)

Company Filing History:

6 out of 537

Icahn School of Medicine at Mount Sinai

patents

6 out of 16,025

University of California

patents

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12667570 - SMALL MOLECULE MODULATORS OF KSR-BOUND MEK (2026-06-30),

2. 11066370 - Kinase inhibitor compounds, compositions, and methods of treating cancer (2021-07-20),

3. 10548897 - KSR antagonists (2020-02-04),

4. 10519113 - Kinase inhibitor compounds, compositions, and methods of treating cancer (2019-12-31),

5. 9895373 - Substituted pyrazolo[3,4-D]pyrimidines and uses thereof (2018-02-20),

6. 9382230 - Methods and compositions for modulating Ire1, SRC and ABL activity (2016-07-05),

7. 9321772 - Substituted pyrazolo[3,4-D]pyrimidines and uses thereof (2016-04-26),

8. 8980899 - Methods of inhibiting Ire1 (2015-03-17),

9. 8815885 - Methods and compositions for modulating IRE1, SRC, and ABL activity (2014-08-26),

10. 8697709 - Fused ring heteroaryl kinase inhibitors (2014-04-15),

Title: Arvin C Dar: Innovator in Cancer Treatment

Introduction

Arvin C Dar is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of cancer treatment through his innovative research and development of kinase inhibitor compounds. With a total of 10 patents to his name, Dar's work has the potential to impact the lives of many patients battling cancer.

Latest Patents

Among his latest patents, Dar has developed compounds that serve as kinase inhibitors, which are crucial in the treatment of cancer. One of his notable inventions relates to a compound having a specific structure, which includes various components as described in his patent. This invention not only encompasses the compound itself but also includes compositions containing it and methods for treating cancer in subjects. Another significant patent involves KSR antagonists, which are designed to inhibit the Kinase Suppressor of Ras (KSR). This invention also includes pharmaceutical compositions comprising KSR inhibitors and methods for treating cancer.

Career Highlights

Throughout his career, Arvin C Dar has worked with esteemed institutions such as the University of California and the Icahn School of Medicine at Mount Sinai. His research has focused on developing innovative solutions for cancer treatment, showcasing his dedication to advancing medical science.

Collaborations

Dar has collaborated with notable colleagues in his field, including Kevan M Shokat and Ross L Cagan. These partnerships have further enriched his research and contributed to the development of groundbreaking cancer therapies.

Conclusion

Arvin C Dar's contributions to cancer treatment through his innovative patents and collaborations highlight his role as a leading inventor in the medical field. His work continues to pave the way for advancements in cancer therapies, offering hope to many patients.

Profile summary based on public USPTO records.